1124 related articles for article (PubMed ID: 26886380)
1. Exploring the Microbiome in Heart Failure.
Kitai T; Kirsop J; Tang WH
Curr Heart Fail Rep; 2016 Apr; 13(2):103-9. PubMed ID: 26886380
[TBL] [Abstract][Full Text] [Related]
2. Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis.
Nagatomo Y; Tang WH
J Card Fail; 2015 Dec; 21(12):973-80. PubMed ID: 26435097
[TBL] [Abstract][Full Text] [Related]
3. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
Nanto-Hara F; Kanemitsu Y; Fukuda S; Kikuchi K; Asaji K; Saigusa D; Iwasaki T; Ho HJ; Mishima E; Suzuki T; Suzuki C; Tsukimi T; Matsuhashi T; Oikawa Y; Akiyama Y; Kure S; Owada Y; Tomioka Y; Soga T; Ito S; Abe T
Nephrol Dial Transplant; 2020 Feb; 35(2):250-264. PubMed ID: 31411705
[TBL] [Abstract][Full Text] [Related]
4. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.
Trøseid M; Ueland T; Hov JR; Svardal A; Gregersen I; Dahl CP; Aakhus S; Gude E; Bjørndal B; Halvorsen B; Karlsen TH; Aukrust P; Gullestad L; Berge RK; Yndestad A
J Intern Med; 2015 Jun; 277(6):717-26. PubMed ID: 25382824
[TBL] [Abstract][Full Text] [Related]
5. The gut microbiome, diet, and links to cardiometabolic and chronic disorders.
Aron-Wisnewsky J; Clément K
Nat Rev Nephrol; 2016 Mar; 12(3):169-81. PubMed ID: 26616538
[TBL] [Abstract][Full Text] [Related]
6. The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine-N-oxide (TMAO) in heart failure.
Anderson KM; Ferranti EP; Alagha EC; Mykityshyn E; French CE; Reilly CM
Heart Fail Rev; 2022 Nov; 27(6):2223-2249. PubMed ID: 35726110
[TBL] [Abstract][Full Text] [Related]
7. The Gut Axis Involvement in Heart Failure: Focus on Trimethylamine N-oxide.
Salzano A; Cassambai S; Yazaki Y; Israr MZ; Bernieh D; Wong M; Suzuki T
Heart Fail Clin; 2020 Jan; 16(1):23-31. PubMed ID: 31735312
[TBL] [Abstract][Full Text] [Related]
8. Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
Taguchi K; Fukami K; Elias BC; Brooks CR
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069405
[TBL] [Abstract][Full Text] [Related]
9. TMAO: how gut microbiota contributes to heart failure.
Zhang Y; Wang Y; Ke B; Du J
Transl Res; 2021 Feb; 228():109-125. PubMed ID: 32841736
[TBL] [Abstract][Full Text] [Related]
10. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.
Xu KY; Xia GH; Lu JQ; Chen MX; Zhen X; Wang S; You C; Nie J; Zhou HW; Yin J
Sci Rep; 2017 May; 7(1):1445. PubMed ID: 28469156
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
Belli M; Barone L; Longo S; Prandi FR; Lecis D; Mollace R; Margonato D; Muscoli S; Sergi D; Federici M; Barillà F
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569352
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.
Mamic P; Chaikijurajai T; Tang WHW
J Mol Cell Cardiol; 2021 Mar; 152():105-117. PubMed ID: 33307092
[TBL] [Abstract][Full Text] [Related]
13. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure.
Chen X; Li HY; Hu XM; Zhang Y; Zhang SY
Chin Med J (Engl); 2019 Aug; 132(15):1843-1855. PubMed ID: 31306229
[TBL] [Abstract][Full Text] [Related]
14. Trimethylamine N-oxide in cardiovascular disease.
Konieczny RA; Kuliczkowski W
Adv Clin Exp Med; 2022 Aug; 31(8):913-925. PubMed ID: 35438848
[TBL] [Abstract][Full Text] [Related]
15. The gut microbiome and heart failure: A better gut for a better heart.
Branchereau M; Burcelin R; Heymes C
Rev Endocr Metab Disord; 2019 Dec; 20(4):407-414. PubMed ID: 31705258
[TBL] [Abstract][Full Text] [Related]
16. Metagenomic analysis of gut microbiota reveals its role in trimethylamine metabolism in heart failure.
Emoto T; Hayashi T; Tabata T; Yamashita T; Watanabe H; Takahashi T; Gotoh Y; Kami K; Yoshida N; Saito Y; Tanaka H; Matsumoto K; Hayashi T; Yamada T; Hirata KI
Int J Cardiol; 2021 Sep; 338():138-142. PubMed ID: 34102245
[TBL] [Abstract][Full Text] [Related]
17. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity.
Sun G; Yin Z; Liu N; Bian X; Yu R; Su X; Zhang B; Wang Y
Biochem Biophys Res Commun; 2017 Nov; 493(2):964-970. PubMed ID: 28942145
[TBL] [Abstract][Full Text] [Related]
18. Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
Li DY; Tang WHW
Semin Nephrol; 2018 Mar; 38(2):193-205. PubMed ID: 29602401
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
[TBL] [Abstract][Full Text] [Related]
20. Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis.
Yuzefpolskaya M; Bohn B; Javaid A; Mondellini GM; Braghieri L; Pinsino A; Onat D; Cagliostro B; Kim A; Takeda K; Naka Y; Farr M; Sayer GT; Uriel N; Nandakumar R; Mohan S; Colombo PC; Demmer RT
Circ Heart Fail; 2021 Jun; 14(6):e007909. PubMed ID: 34129361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
